Vimarsana
Biggest News Aggregation in the World

Runway Extends News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Runway Extends. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Runway Extends Today - Breaking & Trending Today

G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights - Vimarsana News

G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights

Published: May 1, 2024

01.05.2024 - - Achieved $14.1 Million in Net Revenue from Sales of COSELA (trilaciclib) for First Quarter 2024 - - Reaffirmed 2024 Net COSELA Revenue Guidance of $60 to $70 Million - - Announced That Updated Efficacy Results from Phase 2 Trial of Trilaciclib ...

Source: wallstreet-online.de
Related Topics:
Jack BaileyJohnw UmsteadDrug Administration OnPepper Bio IncInvestor Relations Corporate CommunicationsTherapeutics IncExchange CommissionDrug AdministrationThat Final AnalysisEvaluating Overall SurvivalMetastatic Triple Negative Breast CancerLate Second QuarterRunway ExpectedThird QuarterHost WebcastConference CallChief Executive OfficerRunway ExtendsEfficacy ResultsPoster PresentationNew Drug ApplicationLicense AgreementPepper BioPrivate Securities Litigation Reform ActInvestor Relations
Oncology Stock News Bite - G1 Therapeutics (NASDAQ: GTHX) Trades Up on Fourth Quarter and Full Year 2023 Financial Results - Vimarsana News

Oncology Stock News Bite - G1 Therapeutics (NASDAQ: GTHX) Trades Up on Fourth Quarter and Full Year 2023 Financial Results

Published: February 28, 2024

Oncology Stock News Bite - G1 Therapeutics (NASDAQ: GTHX) Trades Up on Fourth Quarter and Full Year 2023 Financial Results

Source: investorideas.com
Related Topics:
Jack BaileyDrug AdministrationTherapeutics IncData Monitoring CommitteeOncology Stock News BitesChief Executive OfficerFourth QuarterFull YearRunway ExtendsMetastatic Triple Negative Breast CancerThird QuarterIndependent Data Monitoring CommitteeExploring MiningCrypto CornerCannabis NewsG1 TherapeuticsFourth QuarterUll Year 2023Financial Results